Overbrook Management Corp lessened its holdings in shares of FibroGen, Inc (NASDAQ:FGEN) by 7.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,220 shares of the biopharmaceutical company’s stock after selling 4,100 shares during the period. Overbrook Management Corp owned approximately 0.07% of FibroGen worth $1,687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. SG Americas Securities LLC raised its holdings in shares of FibroGen by 6.5% during the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 412 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of FibroGen by 0.4% during the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after purchasing an additional 504 shares during the last quarter. Rothschild Asset Management Inc. raised its holdings in shares of FibroGen by 0.5% during the first quarter. Rothschild Asset Management Inc. now owns 186,005 shares of the biopharmaceutical company’s stock worth $4,585,000 after purchasing an additional 959 shares during the last quarter. OppenheimerFunds Inc. raised its holdings in shares of FibroGen by 0.3% during the first quarter. OppenheimerFunds Inc. now owns 356,236 shares of the biopharmaceutical company’s stock worth $8,781,000 after purchasing an additional 1,066 shares during the last quarter. Finally, American International Group Inc. raised its holdings in shares of FibroGen by 7.1% during the first quarter. American International Group Inc. now owns 32,248 shares of the biopharmaceutical company’s stock worth $795,000 after purchasing an additional 2,134 shares during the last quarter. 47.49% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/13/overbrook-management-corp-sells-4100-shares-of-fibrogen-inc-fgen.html.

In other FibroGen news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $29.40, for a total transaction of $1,135,898.40. Following the completion of the transaction, the chief executive officer now owns 3,330,780 shares in the company, valued at approximately $97,924,932. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Pat Cotroneo sold 95,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the transaction, the vice president now owns 173,366 shares of the company’s stock, valued at approximately $8,774,053.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 461,726 shares of company stock valued at $18,362,730. 14.90% of the stock is owned by insiders.

FGEN has been the subject of several recent research reports. Jefferies Group LLC reissued a “buy” rating and set a $75.00 target price on shares of FibroGen in a report on Tuesday. Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a report on Friday, July 21st. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Citigroup Inc. reissued a “buy” rating and set a $48.00 target price on shares of FibroGen in a report on Monday, June 26th. Finally, Stifel Nicolaus raised their target price on shares of FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $60.17.

FibroGen, Inc (FGEN) traded up 3.71% on Wednesday, reaching $51.70. 735,636 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $41.43 and a 200-day moving average price of $31.39. FibroGen, Inc has a 1-year low of $15.60 and a 1-year high of $52.50. The company’s market capitalization is $3.68 billion.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The firm had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities research analysts expect that FibroGen, Inc will post ($1.80) earnings per share for the current year.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.